A. Ganesan

Professor

  • 1.50 Chemistry

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

ResearcherID profilehttp://www.researcherid.com/rid/F-6698-2011

PhD Positions

Click here for current PhD opportunities in PHA. But feel free to email me to discuss projects outside these areas and alternative sources of funding.

Ganesan obtained a BSc (Hons) in Chemistry at the National University of Singapore (1986). He completed his PhD in synthetic methodology and total synthesis under the supervision of Clayton Heathcock at the Department of Chemistry, University of California-Berkeley (1992) and was subsequently a postdoctoral fellow with Gregory Verdine at the Department of Chemistry at Harvard University. In 1993, he joined the Institute of Molecular and Cell Biology in Singapore as a Senior Research Chemist at the Centre for Natural Product Research and in 1996 became Principal Investigator of the Institute’s Medicinal and Combinatorial Chemistry group. In 1999 he joined the University of Southampton as a Reader in the Combinatorial Chemistry Centre for Excellence. In 2011 he became the Chair of Chemical Biology at UEA’s School of Pharmacy. He is Director of Postgraduate Research and Head of the Healthy Ageing research theme within the School. 

Ganesan is co-founder of the biotech company Karus Therapeutics and Chair of the EU COST Action CM1406, 'Epigenetic Chemical Biology'. He sits on the IUPAC Subcommittee for Medicinal Chemistry and Drug Development and the Royal Society of Chemistry's Bioorganic & Medicinal Chemistry Sector committee.

Ganesan's research centres around chemical biology, medicinal chemistry and organic synthesis with an emphasis on biologically active natural products and epigenetics.

Selected publications

Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore

Davidson, S. M.; Foote, K.; Kunuthur, S.; Gosain, R.; Tan, N.; Tyser, R.; Zhao, Y. J.; Graeff, R.; Ganesan, A.; Duchen, M. R.; Patel, S.; Yellon, D. M.
Cardiovasc. Res. 2015, 108, 357–366.
DOI: 10.1093/cvr/cvv226

Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase
Tortorici, M.; Borrello, M. T.; Tardugno, M.; Chiarelli, L. R.; Pilotto, S.; Ciossani, G.; Vellore, N. A.; Bailey, S. G.; Cowan, J.; O’Connell, M.; Crabb, S. J.; Packham, G.; Mai, A.; Baron, R.; Ganesan, A.; Mattevi, A. 
ACS Chem. Biol. 2013, 8, 1677–1682.
DOI: 10.1021//cb4001926

Total Synthesis and Stereochemical Assignment of Burkholdac B, a Depsipeptide HDAC Inhibitor
Benelkebir, H.; Donlevy, A. M.; Packham, G.; Ganesan, A
Org. Lett. 2011, 13, 6334–6337.
DOI: 10.1021/ol202197q

Determination of Molecular Torsion Angles Using Nuclear Singlet Relaxation
Tayler, M. C. D.; Marie, S.; Ganesan, A.; Levitt, M. H.
J. Am. Chem. Soc. 2010, 132, 8225–8227.
DOI: 10.1021/ja1012917

Identification of a Chemical Probe for NAADP by Virtual Screening
Naylor, E.; Arredouani, A.; Vasudevan, S. R.; Lewis, A. M.; Parkesh, R.; Mizote, A.; Rosen, D.; Thomas, J. M.; Izumi, M.; Ganesan, A.; Galione, A.; Churchill, G. C.
Nat. Chem. Biol. 2009, 5, 220-226.
DOI: 10.1038/nchembio.150
 

External Activities

  • 2010 - Chairman, EU COST Action ‘Epigenetics: Bench to Bedside’
  • 2007-2011 - Member, Organic Division Executive, Royal Society of Chemistry
  • 2006 - Committee Member, IUPAC Subcommitee for Medicinal Chemistry and Drug Development
  • 2006 - Treasurer, High-throughput Chemistry and New Technologies Subject Group, Royal Society of Chemistry
  • 2004 - Visiting professorship at Tokyo Institute of Technology, Japan Society for the Promotion of Science

Key Research Interests and Expertise

Cancer Research UK
Histone Methylation Inhibitors
G. Packham (U. Southampton) and A. Ganesan
2007-2011
£91,000

BBSRC
NAADP Receptor Antagonists
A. Gansan
2009-2012
£351,000

Professional Activities

Patents

  • Packham, G. K.; Ganesan, A.; Mann, D. A.; Oakley, F.; Srinivasan, N. Sulfasalazine Analogues as NF- Inhibitors. WO2006072783.
  • Packham, G. K.; Ganesan, A.; Yurek-George, A.; Cecil, A. R. L. FK228 Derivates as HDAC Inhibitors. WO2006129105.
  • Packham, G. K.; Ganesan, A.; Cecil, A. R. L. Depsipeptides and their Therapeutic Use. WO2008062201.
  • Packham, G. K.; Ganesan, A.; Cecil, A. R. L. Depsipeptides and their Therapeutic Use. WO2008062232.
  • Rahman, Atta-ur; Choudhary, M. I.; Shaheen, F.; Ganesan, A.; Simjee, S. U.; Raza, A. M. New Anticonvulsant Compounds. US2008004353.

Specialisms

Medicines and health; discovery of new drugs; epigenetics - effect of genetics versus environment on health; organic chemistry; chemical biology.

Areas Of Expertise

CHEMICAL BIOLOGY||DRUG DISCOVERY||DRUG DISCOVERY||MEDICINES AND HEALTH||MEDICINES AND HEALTH||ORGANIC CHEMISTRY

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or